Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies

Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline

HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases

Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia

Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology

Booster Therapeutics launches with $15 M seed financing led by Apollo Health Ventures and Novo Holdings

HAYA Therapeutics enters partnership with Eli Lilly worth up to $1 B to discover new genome targets for obesity and related metabolic conditions

GSK enters into a multi-year data licence agreement with Ochre Bio